Literature DB >> 19522921

[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris].

Ulrich Mrowietz1, Martin Rostami-Yazdi, Marcus Neureither, Kristian Reich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19522921     DOI： 10.1111/j.1610-0387.2009.07059.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  5 in total

Review 1.  [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Authors:  F Behrens; D Thaçi; J Wollenhaupt; K Krüger
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

Review 2.  [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Authors:  F Behrens; D Thaçi; J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2016-06       Impact factor: 1.372

3.  Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.

Authors:  H Dickel; T Bruckner; P Altmeyer
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-18       Impact factor: 6.166

4.  Fumaric acid esters in dermatology.

Authors:  Uwe Wollina
Journal:  Indian Dermatol Online J       Date:  2011-07

Review 5.  Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.

Authors:  Serena Ruggieri; Carla Tortorella; Claudio Gasperini
Journal:  Ther Clin Risk Manag       Date:  2014-03-27       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.